GENTAUR Molecular Products.
Monoclonal Antibody, ELISA Kit, Polyclonal Antibody, Recombinant/Purified Protein.Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery
Complement component C8 beta chain (Complement component 8 subunit beta)
CO8B_HUMAN Reviewed; 591 AA.
P07358; A1L4K7;
01-APR-1988, integrated into UniProtKB/Swiss-Prot.
23-JAN-2002, sequence version 3.
28-FEB-2018, entry version 180.
RecName: Full=Complement component C8 beta chain;
AltName: Full=Complement component 8 subunit beta;
Flags: Precursor;
Name=C8B;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND
GLYCOSYLATION.
TISSUE=Liver;
PubMed=2820472; DOI=10.1021/bi00386a047;
Howard O.M.Z., Rao A.G., Sodetz J.M.;
"Complementary DNA and derived amino acid sequence of the beta subunit
of human complement protein C8: identification of a close structural
and ancestral relationship to the alpha subunit and C9.";
Biochemistry 26:3565-3570(1987).
[2]
SEQUENCE REVISION.
Sodetz J.M.;
Submitted (JUN-1988) to the EMBL/GenBank/DDBJ databases.
[3]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Liver;
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-117.
PubMed=16710414; DOI=10.1038/nature04727;
Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
Beck S., Rogers J., Bentley D.R.;
"The DNA sequence and biological annotation of human chromosome 1.";
Nature 441:315-321(2006).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
Venter J.C.;
Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[7]
NUCLEOTIDE SEQUENCE [MRNA] OF 47-591, AND PROTEIN SEQUENCE OF 55-68.
TISSUE=Liver;
PubMed=3651397; DOI=10.1021/bi00386a045;
Haefliger J.-A., Tschopp J., Nardelli D., Wahli W., Kocher H.-P.,
Tosi M., Stanley K.K.;
"Complementary DNA cloning of complement C8 beta and its sequence
homology to C9.";
Biochemistry 26:3551-3556(1987).
[8]
PARTIAL PROTEIN SEQUENCE, CHARACTERIZATION, AND SUBUNIT.
PubMed=7440581;
Steckel E.W., York R.G., Monahan J.B., Sodetz J.M.;
"The eighth component of human complement. Purification and
physicochemical characterization of its unusual subunit structure.";
J. Biol. Chem. 255:11997-12005(1980).
[9]
GLYCOSYLATION AT TRP-70; TRP-73; TRP-551 AND TRP-554.
PubMed=10551839; DOI=10.1074/jbc.274.46.32786;
Hofsteenge J., Blommers M., Hess D., Furmanek A., Miroshnichenko O.;
"The four terminal components of the complement system are C-
mannosylated on multiple tryptophan residues.";
J. Biol. Chem. 274:32786-32794(1999).
[10]
GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-243.
TISSUE=Plasma;
PubMed=16335952; DOI=10.1021/pr0502065;
Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
Moore R.J., Smith R.D.;
"Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
hydrazide chemistry, and mass spectrometry.";
J. Proteome Res. 4:2070-2080(2005).
[11]
GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-243.
TISSUE=Liver;
PubMed=19159218; DOI=10.1021/pr8008012;
Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
"Glycoproteomics analysis of human liver tissue by combination of
multiple enzyme digestion and hydrazide chemistry.";
J. Proteome Res. 8:651-661(2009).
[12]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Liver;
PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
Wang L., Ye M., Zou H.;
"An enzyme assisted RP-RPLC approach for in-depth analysis of human
liver phosphoproteome.";
J. Proteomics 96:253-262(2014).
[13]
X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 55-591, PHOSPHORYLATION AT
THR-418, SUBUNIT, AND DISULFIDE BONDS.
PubMed=21454577; DOI=10.1074/jbc.M111.219766;
Lovelace L.L., Cooper C.L., Sodetz J.M., Lebioda L.;
"Structure of human C8 protein provides mechanistic insight into
membrane pore formation by complement.";
J. Biol. Chem. 286:17585-17592(2011).
[14]
VARIANT GLY-117, AND DEFINITION OF ALLOTYPES C8B A AND C8B B.
PubMed=8131848; DOI=10.1016/0014-5793(94)80140-1;
Dewald G., Hemmer S., Noethen M.M.;
"Human complement component C8. Molecular basis of the beta-chain
polymorphism.";
FEBS Lett. 340:211-215(1994).
-!- FUNCTION: Constituent of the membrane attack complex (MAC) that
plays a key role in the innate and adaptive immune response by
forming pores in the plasma membrane of target cells.
-!- SUBUNIT: Heterotrimer of 3 chains: alpha, beta and gamma. The
alpha and gamma chains are disulfide bonded. Component of the
membrane attack complex (MAC). MAC assembly is initiated by
proteolytic cleavage of C5 into C5a and C5b. C5b binds
sequentially C6, C7, C8 and multiple copies of the pore-forming
subunit C9. {ECO:0000269|PubMed:21454577,
ECO:0000269|PubMed:7440581}.
-!- SUBCELLULAR LOCATION: Secreted.
-!- PTM: N-glycosylated; contains one or two bound glycans. Not O-
glycosylated. {ECO:0000269|PubMed:10551839,
ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
ECO:0000269|PubMed:2820472}.
-!- POLYMORPHISM: The sequence shown is that of allotype C8B B.
-!- DISEASE: Complement component 8 deficiency, 2 (C8D2) [MIM:613789]:
A rare defect of the complement classical pathway associated with
susceptibility to severe recurrent infections, predominantly by
Neisseria gonorrhoeae or Neisseria meningitidis. Note=Disease
susceptibility is associated with variations affecting the gene
represented in this entry.
-!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
{ECO:0000305}.
-!- WEB RESOURCE: Name=C8Bbase; Note=C8B mutation db;
URL="http://structure.bmc.lu.se/idbase/C8Bbase/";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; M16973; AAA51862.1; -; mRNA.
EMBL; AK313382; BAG36180.1; -; mRNA.
EMBL; AL121998; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; CH471059; EAX06641.1; -; Genomic_DNA.
EMBL; BC130575; AAI30576.1; -; mRNA.
EMBL; X04393; CAA27981.1; -; mRNA.
CCDS; CCDS30730.1; -.
PIR; A43071; C8HUB.
RefSeq; NP_000057.2; NM_000066.3.
RefSeq; XP_016857724.1; XM_017002235.1.
UniGene; Hs.391835; -.
PDB; 3OJY; X-ray; 2.51 A; B=55-591.
PDBsum; 3OJY; -.
ProteinModelPortal; P07358; -.
SMR; P07358; -.
BioGrid; 107193; 6.
STRING; 9606.ENSP00000360281; -.
iPTMnet; P07358; -.
PhosphoSitePlus; P07358; -.
DMDM; 20141201; -.
PaxDb; P07358; -.
PeptideAtlas; P07358; -.
PRIDE; P07358; -.
DNASU; 732; -.
Ensembl; ENST00000371237; ENSP00000360281; ENSG00000021852.
GeneID; 732; -.
KEGG; hsa:732; -.
UCSC; uc001cyp.5; human.
CTD; 732; -.
DisGeNET; 732; -.
EuPathDB; HostDB:ENSG00000021852.12; -.
GeneCards; C8B; -.
HGNC; HGNC:1353; C8B.
HPA; HPA023694; -.
MalaCards; C8B; -.
MIM; 120960; gene.
MIM; 613789; phenotype.
neXtProt; NX_P07358; -.
Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
PharmGKB; PA25952; -.
eggNOG; ENOG410IE7H; Eukaryota.
eggNOG; ENOG410Y2J1; LUCA.
HOGENOM; HOG000231146; -.
HOVERGEN; HBG106489; -.
InParanoid; P07358; -.
KO; K03998; -.
OrthoDB; EOG091G07LK; -.
PhylomeDB; P07358; -.
TreeFam; TF330498; -.
Reactome; R-HSA-166665; Terminal pathway of complement.
Reactome; R-HSA-977606; Regulation of Complement cascade.
ChiTaRS; C8B; human.
EvolutionaryTrace; P07358; -.
GenomeRNAi; 732; -.
PRO; PR:P07358; -.
Proteomes; UP000005640; Chromosome 1.
Bgee; ENSG00000021852; -.
CleanEx; HS_C8B; -.
ExpressionAtlas; P07358; baseline and differential.
Genevisible; P07358; HS.
GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
GO; GO:0005576; C:extracellular region; TAS:Reactome.
GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
GO; GO:0016020; C:membrane; TAS:ProtInc.
GO; GO:0005579; C:membrane attack complex; IDA:UniProtKB.
GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
GO; GO:0006956; P:complement activation; TAS:ProtInc.
GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
GO; GO:0006955; P:immune response; TAS:ProtInc.
GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
CDD; cd00112; LDLa; 1.
Gene3D; 2.20.100.10; -; 2.
InterPro; IPR037566; Complement_C8_beta.
InterPro; IPR036055; LDL_receptor-like_sf.
InterPro; IPR023415; LDLR_class-A_CS.
InterPro; IPR002172; LDrepeatLR_classA_rpt.
InterPro; IPR001862; MAC_perforin.
InterPro; IPR020864; MACPF.
InterPro; IPR020863; MACPF_CS.
InterPro; IPR000884; TSP1_rpt.
InterPro; IPR036383; TSP1_rpt_sf.
PANTHER; PTHR19325:SF401; PTHR19325:SF401; 1.
Pfam; PF00057; Ldl_recept_a; 1.
Pfam; PF01823; MACPF; 1.
Pfam; PF00090; TSP_1; 2.
PRINTS; PR00764; COMPLEMENTC9.
SMART; SM00192; LDLa; 1.
SMART; SM00457; MACPF; 1.
SMART; SM00209; TSP1; 2.
SUPFAM; SSF57424; SSF57424; 1.
SUPFAM; SSF82895; SSF82895; 2.
PROSITE; PS00022; EGF_1; 1.
PROSITE; PS01209; LDLRA_1; 1.
PROSITE; PS50068; LDLRA_2; 1.
PROSITE; PS00279; MACPF_1; 1.
PROSITE; PS51412; MACPF_2; 1.
PROSITE; PS50092; TSP1; 2.
1: Evidence at protein level;
3D-structure; Complement alternate pathway; Complement pathway;
Complete proteome; Cytolysis; Direct protein sequencing;
Disulfide bond; EGF-like domain; Glycoprotein; Immunity;
Innate immunity; Membrane attack complex; Phosphoprotein;
Polymorphism; Reference proteome; Repeat; Secreted; Signal.
SIGNAL 1 32 {ECO:0000255}.
PROPEP 33 54 {ECO:0000269|PubMed:3651397}.
/FTId=PRO_0000023591.
CHAIN 55 591 Complement component C8 beta chain.
/FTId=PRO_0000023592.
DOMAIN 64 117 TSP type-1 1. {ECO:0000255|PROSITE-
ProRule:PRU00210}.
DOMAIN 120 157 LDL-receptor class A.
{ECO:0000255|PROSITE-ProRule:PRU00124}.
DOMAIN 158 504 MACPF. {ECO:0000255|PROSITE-
ProRule:PRU00745}.
DOMAIN 505 535 EGF-like.
DOMAIN 545 591 TSP type-1 2. {ECO:0000255|PROSITE-
ProRule:PRU00210}.
MOD_RES 418 418 Phosphothreonine.
{ECO:0000269|PubMed:21454577}.
CARBOHYD 70 70 C-linked (Man) tryptophan.
{ECO:0000269|PubMed:10551839}.
CARBOHYD 73 73 C-linked (Man) tryptophan.
{ECO:0000269|PubMed:10551839}.
CARBOHYD 101 101 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
CARBOHYD 243 243 N-linked (GlcNAc...) asparagine.
{ECO:0000269|PubMed:16335952,
ECO:0000269|PubMed:19159218}.
CARBOHYD 551 551 C-linked (Man) tryptophan.
{ECO:0000269|PubMed:10551839}.
CARBOHYD 554 554 C-linked (Man) tryptophan.
{ECO:0000269|PubMed:10551839}.
DISULFID 65 100 {ECO:0000269|PubMed:21454577}.
DISULFID 76 110 {ECO:0000269|PubMed:21454577}.
DISULFID 79 116 {ECO:0000269|PubMed:21454577}.
DISULFID 122 133 {ECO:0000269|PubMed:21454577}.
DISULFID 127 146 {ECO:0000269|PubMed:21454577}.
DISULFID 140 155 {ECO:0000269|PubMed:21454577}.
DISULFID 378 403 {ECO:0000269|PubMed:21454577}.
DISULFID 503 550 {ECO:0000269|PubMed:21454577}.
DISULFID 505 521 {ECO:0000269|PubMed:21454577}.
DISULFID 508 523 {ECO:0000269|PubMed:21454577}.
DISULFID 525 534 {ECO:0000269|PubMed:21454577}.
DISULFID 557 590 {ECO:0000269|PubMed:21454577}.
VARIANT 108 108 E -> K (in dbSNP:rs12067507).
/FTId=VAR_027649.
VARIANT 117 117 R -> G (in allotype C8B A;
dbSNP:rs1013579).
{ECO:0000269|PubMed:16710414,
ECO:0000269|PubMed:8131848}.
/FTId=VAR_012642.
VARIANT 261 261 P -> L (in dbSNP:rs12085435).
/FTId=VAR_027650.
TURN 78 81 {ECO:0000244|PDB:3OJY}.
STRAND 82 86 {ECO:0000244|PDB:3OJY}.
STRAND 89 91 {ECO:0000244|PDB:3OJY}.
STRAND 104 109 {ECO:0000244|PDB:3OJY}.
STRAND 123 126 {ECO:0000244|PDB:3OJY}.
TURN 128 130 {ECO:0000244|PDB:3OJY}.
HELIX 136 138 {ECO:0000244|PDB:3OJY}.
STRAND 141 143 {ECO:0000244|PDB:3OJY}.
STRAND 146 149 {ECO:0000244|PDB:3OJY}.
HELIX 172 176 {ECO:0000244|PDB:3OJY}.
STRAND 177 179 {ECO:0000244|PDB:3OJY}.
TURN 181 183 {ECO:0000244|PDB:3OJY}.
STRAND 186 189 {ECO:0000244|PDB:3OJY}.
STRAND 201 205 {ECO:0000244|PDB:3OJY}.
STRAND 208 212 {ECO:0000244|PDB:3OJY}.
STRAND 216 221 {ECO:0000244|PDB:3OJY}.
STRAND 229 236 {ECO:0000244|PDB:3OJY}.
HELIX 237 240 {ECO:0000244|PDB:3OJY}.
TURN 256 258 {ECO:0000244|PDB:3OJY}.
TURN 269 271 {ECO:0000244|PDB:3OJY}.
STRAND 272 275 {ECO:0000244|PDB:3OJY}.
HELIX 276 283 {ECO:0000244|PDB:3OJY}.
STRAND 290 297 {ECO:0000244|PDB:3OJY}.
STRAND 299 306 {ECO:0000244|PDB:3OJY}.
STRAND 308 310 {ECO:0000244|PDB:3OJY}.
HELIX 315 321 {ECO:0000244|PDB:3OJY}.
HELIX 330 340 {ECO:0000244|PDB:3OJY}.
STRAND 342 352 {ECO:0000244|PDB:3OJY}.
STRAND 355 361 {ECO:0000244|PDB:3OJY}.
HELIX 362 365 {ECO:0000244|PDB:3OJY}.
TURN 366 369 {ECO:0000244|PDB:3OJY}.
HELIX 372 378 {ECO:0000244|PDB:3OJY}.
TURN 379 381 {ECO:0000244|PDB:3OJY}.
TURN 404 408 {ECO:0000244|PDB:3OJY}.
HELIX 409 412 {ECO:0000244|PDB:3OJY}.
TURN 413 415 {ECO:0000244|PDB:3OJY}.
STRAND 419 426 {ECO:0000244|PDB:3OJY}.
HELIX 435 439 {ECO:0000244|PDB:3OJY}.
STRAND 441 443 {ECO:0000244|PDB:3OJY}.
HELIX 449 457 {ECO:0000244|PDB:3OJY}.
STRAND 461 469 {ECO:0000244|PDB:3OJY}.
HELIX 470 473 {ECO:0000244|PDB:3OJY}.
TURN 476 478 {ECO:0000244|PDB:3OJY}.
HELIX 482 499 {ECO:0000244|PDB:3OJY}.
HELIX 502 504 {ECO:0000244|PDB:3OJY}.
STRAND 513 517 {ECO:0000244|PDB:3OJY}.
STRAND 520 524 {ECO:0000244|PDB:3OJY}.
HELIX 532 534 {ECO:0000244|PDB:3OJY}.
STRAND 536 541 {ECO:0000244|PDB:3OJY}.
STRAND 557 563 {ECO:0000244|PDB:3OJY}.
STRAND 584 588 {ECO:0000244|PDB:3OJY}.
SEQUENCE 591 AA; 67047 MW; B01722A6F2E9AFCE CRC64;
MKNSRTWAWR APVELFLLCA ALGCLSLPGS RGERPHSFGS NAVNKSFAKS RQMRSVDVTL
MPIDCELSSW SSWTTCDPCQ KKRYRYAYLL QPSQFHGEPC NFSDKEVEDC VTNRPCRSQV
RCEGFVCAQT GRCVNRRLLC NGDNDCGDQS DEANCRRIYK KCQHEMDQYW GIGSLASGIN
LFTNSFEGPV LDHRYYAGGC SPHYILNTRF RKPYNVESYT PQTQGKYEFI LKEYESYSDF
ERNVTEKMAS KSGFSFGFKI PGIFELGISS QSDRGKHYIR RTKRFSHTKS VFLHARSDLE
VAHYKLKPRS LMLHYEFLQR VKRLPLEYSY GEYRDLFRDF GTHYITEAVL GGIYEYTLVM
NKEAMERGDY TLNNVHACAK NDFKIGGAIE EVYVSLGVSV GKCRGILNEI KDRNKRDTMV
EDLVVLVRGG ASEHITTLAY QELPTADLMQ EWGDAVQYNP AIIKVKVEPL YELVTATDFA
YSSTVRQNMK QALEEFQKEV SSCHCAPCQG NGVPVLKGSR CDCICPVGSQ GLACEVSYRK
NTPIDGKWNC WSNWSSCSGR RKTRQRQCNN PPPQNGGSPC SGPASETLDC S
Related products :
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com | Gentaur
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
RCS Paris B 484 237 888
SIRET 48423788800017
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
france@gentaur.com | Gentaur
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur
GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel: 0208-080893 Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62 SWIFT RABONL2U
GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur
ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX 058 710 33 48
poland@gentaur.com | Gentaur
Other countries
Österreich +43720880899
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Danmark +4569918806
Finland Helsset +358942419041
Magyarország Budapest +3619980547
Ireland Dublin+35316526556
Luxembourg+35220880274
Norge Oslo+4721031366
Sverige Stockholm+46852503438
Schweiz Züri+41435006251
US New York+17185132983
GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur
Pathways :
WP1614: 1- and 2-Methylnaphthalene degradation
WP1566: Citrate cycle (TCA cycle)
WP1655: Geraniol degradation
WP542: Electron Transport Chain
WP1045: TGF-beta Receptor Signaling Pathway
WP1048: TGF Beta Signaling Pathway
WP105: Fatty Acid Beta Oxidation 2
WP1056: Complement and Coagulation Cascades
WP1058: Senescence and Autophagy
WP1061: Fatty Acid Beta Oxidation
WP1095: Complement Activation, Classical Pathway
WP1106: Keap1-Nrf2
WP1107: Mitochondrial LC-Fatty Acid Beta-Oxidation
WP113: TGF Beta Signaling Pathway
WP1161: TGF-beta Receptor Signaling Pathway
WP1164: TGF Beta Signaling Pathway
WP1172: Complement and Coagulation Cascades
WP1177: Fatty Acid Beta Oxidation
WP1207: Fatty Acid Beta Oxidation
WP1224: EBV LMP1 signaling
WP1225: estrogen signalling
WP1226: Mitochondrial LC-Fatty Acid Beta-Oxidation
WP1237: Fatty Acid Beta Oxidation
WP126: Fatty Acid Beta Oxidation 1
WP1269: Fatty Acid Beta Oxidation
Related Genes :
[C3 CPAMD1] Complement C3 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1) [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]
[C3] Complement C3 (HSE-MSF) [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]
[C3] Complement C3 [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc) (Neutrophil chemotactic factor-2) (ENCF-2); Complement C3 alpha chain; C3a anaphylatoxin (Neutrophil chemotactic factor-1) (ENCF-1); Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]
[C3] Complement C3 [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]
[c3] Complement C3 [Cleaved into: Complement C3 beta chain; Complement C3 alpha chain; C3a anaphylatoxin; Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2] (Fragment)
[C3] Complement C3 [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]
[C3] Complement C3 [Cleaved into: Complement C3 beta chain; Complement C3 alpha chain; C3a anaphylatoxin; C3-beta-c (C3bc); Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]
[C4A CO4 CPAMD2] Complement C4-A (Acidic complement C4) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2) [Cleaved into: Complement C4 beta chain; Complement C4-A alpha chain; C4a anaphylatoxin; C4b-A; C4d-A; Complement C4 gamma chain]
[C4B CO4 CPAMD3; C4B_2] Complement C4-B (Basic complement C4) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3) [Cleaved into: Complement C4 beta chain; Complement C4-B alpha chain; C4a anaphylatoxin; C4b-B; C4d-B; Complement C4 gamma chain]
[C5 Hc] Complement C5 (Hemolytic complement) [Cleaved into: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' chain]
[C5 CPAMD4] Complement C5 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4) [Cleaved into: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' chain]
[C1S] Complement C1s subcomponent (EC 3.4.21.42) (C1 esterase) (Complement component 1 subcomponent s) [Cleaved into: Complement C1s subcomponent heavy chain; Complement C1s subcomponent light chain]
[C1R] Complement C1r subcomponent (EC 3.4.21.41) (Complement component 1 subcomponent r) [Cleaved into: Complement C1r subcomponent heavy chain; Complement C1r subcomponent light chain]
[C4b C4] Complement C4-B [Cleaved into: Complement C4 beta chain; Complement C4 alpha chain; C4a anaphylatoxin; Complement C4 gamma chain]
[CLU APOJ CLI KUB1 AAG4] Clusterin (Aging-associated gene 4 protein) (Apolipoprotein J) (Apo-J) (Complement cytolysis inhibitor) (CLI) (Complement-associated protein SP-40,40) (Ku70-binding protein 1) (NA1/NA2) (Testosterone-repressed prostate message 2) (TRPM-2) [Cleaved into: Clusterin beta chain (ApoJalpha) (Complement cytolysis inhibitor a chain); Clusterin alpha chain (ApoJbeta) (Complement cytolysis inhibitor b chain)]
[C4 C4a] Complement C4 [Cleaved into: Complement C4 beta chain; Complement C4 alpha chain; C4a anaphylatoxin; Complement C4 gamma chain]
[CFB BF BFD] Complement factor B (EC 3.4.21.47) (C3/C5 convertase) (Glycine-rich beta glycoprotein) (GBG) (PBF2) (Properdin factor B) [Cleaved into: Complement factor B Ba fragment; Complement factor B Bb fragment]
[C2] Complement C2 (EC 3.4.21.43) (C3/C5 convertase) [Cleaved into: Complement C2b fragment; Complement C2a fragment]
[C9] Complement component C9 [Cleaved into: Complement component C9a; Complement component C9b]
[CFI IF] Complement factor I (EC 3.4.21.45) (C3B/C4B inactivator) [Cleaved into: Complement factor I heavy chain; Complement factor I light chain]
[C1s r-gsp] Complement C1s subcomponent (EC 3.4.21.42) (C1 esterase) (Complement component 1 subcomponent s) [Cleaved into: Complement C1s subcomponent heavy chain; Complement C1s subcomponent light chain]
[C8A] Complement component C8 alpha chain (Complement component 8 subunit alpha)
[C8B] Complement component C8 beta chain (Complement component 8 subunit beta)
[Cr1l Crry Cry] Complement component receptor 1-like protein (Complement regulatory protein Crry) (Protein p65)
[MASP1 CRARF CRARF1 PRSS5] Mannan-binding lectin serine protease 1 (EC 3.4.21.-) (Complement factor MASP-3) (Complement-activating component of Ra-reactive factor) (Mannose-binding lectin-associated serine protease 1) (MASP-1) (Mannose-binding protein-associated serine protease) (Ra-reactive factor serine protease p100) (RaRF) (Serine protease 5) [Cleaved into: Mannan-binding lectin serine protease 1 heavy chain; Mannan-binding lectin serine protease 1 light chain]
[CR2 C3DR] Complement receptor type 2 (Cr2) (Complement C3d receptor) (Epstein-Barr virus receptor) (EBV receptor) (CD antigen CD21)
[Masp1 Crarf Masp3] Mannan-binding lectin serine protease 1 (EC 3.4.21.-) (Complement factor MASP-3) (Complement-activating component of Ra-reactive factor) (Mannose-binding lectin-associated serine protease 1) (MASP-1) (Mannose-binding protein-associated serine protease) (Ra-reactive factor serine protease p100) (RaRF) (Serine protease 5) [Cleaved into: Mannan-binding lectin serine protease 1 heavy chain; Mannan-binding lectin serine protease 1 light chain]
[Masp1 Crarf Masp3] Mannan-binding lectin serine protease 1 (EC 3.4.21.-) (Complement factor MASP-3) (Complement-activating component of Ra-reactive factor) (Mannose-binding lectin-associated serine protease 1) (MASP-1) (Mannose-binding protein-associated serine protease) (Ra-reactive factor serine protease p100) (RaRF) (Serine protease 5) [Cleaved into: Mannan-binding lectin serine protease 1 heavy chain; Mannan-binding lectin serine protease 1 light chain]
[C1QBP] Complement component 1 Q subcomponent-binding protein, mitochondrial (Globular head receptor of C1 complement protein) (Mitochondrial matrix protein p32)
[Cr1l Crry] Complement component receptor 1-like protein (Antigen 5I2) (Complement regulatory protein Crry)
Bibliography :
No related Items
Enter catalog number :
Favorites Pages:
No Favorits